Physician profile
Charles Lowe
NPI 1740883479
$6,220.74
in general payments reported to CMS, 2019-2025
23 companies · $19.15 in 2025
The $19.15 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,581 · 2022: $1,323 · 2023: $2,630 · 2024: $668 · 2025: $19.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.07 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,487.90 | 2021-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Accurian |
| Collegium Pharmaceutical, INC. | $844.85 | 2021-2024 | Xtampza |
| Abbvie INC. | $573.54 | 2022-2024 | |
| Vertos Medical, INC. | $552.33 | 2023 | Mild Device Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $535.56 | 2021-2024 | Relistor |
| Boston Scientific Corporation | $238.08 | 2021-2023 | Superion Indirect Decompression System |
| Averitas Pharma INC. | $229.08 | 2023 | Qutenza |
| Relievant Medsystems, INC. | $216.22 | 2023 | Intracept |
| Allergan, INC. | $144.94 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $51.93 | 2024 | |
| Azurity Pharmaceuticals, INC. | $49.47 | 2023 | Horizant |
| Biodelivery Sciences International, INC. | $40.55 | 2021 | |
| Horizon Therapeutics Plc | $30.59 | 2021-2022 | |
| Nevro Corp. | $29.34 | 2021 | |
| Vanda Pharmaceuticals INC. | $28.45 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $28.38 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Bioventus LLC | $23.28 | 2021 | |
| Fidia Pharma USA INC. | $22.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.08 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.04 | 2023 | Zilretta |
| Takeda Pharmaceuticals U.S.A., INC. | $19.15 | 2025 | |
| Pfizer INC. | $18.21 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.